An LFJ Conversation with Chris Princis, Executive Vice President, CAMG
Below is our LFJ Conversation with Chris Princis, Executive Vice President at Consumer Attorney Marketing Group (CAMG).
Chris Princis is Executive Vice President of Consumer Attorney Marketing Group (CAMG) and was instrumental in building CAMG Capital Connect, its turn-key litigation finance program. He leads the program’s investor and funder relationships, bringing expertise across legal marketing, mass tort case acquisition, and litigation finance.
Consumer Attorney Marketing Group (CAMG) is the nation’s largest fully-integrated legal marketing and case acquisition agency, with the media, intake, and case development infrastructure that plaintiff law firms rely on to build their dockets. CAMG Capital Connect opens that platform to investors. The turn-key program provides direct access to mass tort and single-event opportunities alongside premier handling firms, with deal-by-deal control over where capital is deployed and transparent reporting from origination through resolution.
To set the stage, give us a snapshot of CAMG. What does the firm do across media buying, creative and the CAMG360 intake and vetting infrastructure, who do you serve, and what differentiates the business in 2026?
CAMG — Consumer Attorney Marketing Group — is a full-service marketing and case-acquisition infrastructure firm built exclusively for the legal industry, with three interlocking pieces:
Media buying and creative. Digital, television, infomercials, radio, and out-of-home, all bought and produced in-house, scaled from a single local market up to national mass tort campaigns. The creative team doesn't just make ads — infomercials and video are treated as a core acquisition channel in their own right, because in mass tort, storytelling drives call volume and case quality simultaneously.
CAMG360. This is the operating system that turns a marketing dollar into a signed, verified case: Plan → Attract → Engage → Convert → Analyze. It wraps media buying together with phone/call handling, contract processing, medical record retrieval and review, and data publishing, so a firm or funder isn't stitching together five vendors — CAMG owns the chain from impression to case-ready file.
Intake and vetting infrastructure. A dedicated internal intake team handles identity verification, medical records retrieval (often inside 48 hours when records are available), and record review/validation, under a standardized, HIPAA-compliant, quality-controlled process — applied the same way regardless of whether CAMG or a partner generated the lead.
Who we serve: plaintiff law firms running local PI and sex-abuse campaigns up through the largest national mass tort litigation groups, and — increasingly — litigation funders and investors who need vetted, case-ready deal flow rather than just marketing services. That's the thinking behind CAMG Capital Connect, our turnkey investment program, and CMIR, our reporting platform for tracking mass tort and single-event portfolios.
What differentiates us in 2026: most competitors are either a marketing shop or a lead broker — not both, and rarely with owned intake and vetting on top. CAMG controls the entire funnel: we buy the media, we answer the phone, we verify the claimant, we pull and review the records, and we hand a funder or firm a case that's already been through a repeatable quality-control process. That vertical integration is what lets us speak credibly to both sides of the table — the law firms who need volume and quality, and the capital providers who need conversion and duration to actually behave like the numbers in their model.
Let's start with the current state of mass torts and case acquisition. How would you characterize the market today in terms of acquisition costs, saturation in the largest torts and claimant supply, and what has changed most for the firms and funders trying to build a book of cases?
The honest characterization: the largest, most established torts are saturated, and acquisition costs reflect it. Camp Lejeune is the clearest example — billions of dollars of funding chased a finite, well-defined claimant pool, and by the time a litigation is a household name with heavy TV spend from every firm in the space, cost-per-case has been bid up while the marginal claimant left in the pool is often a weaker one — later filers, thinner records, more disqualifications. That dynamic — earlier entrants get better economics, later capital chases a shrinking and lower-quality tail — is now a pattern funders explicitly underwrite around rather than a surprise.
What has changed most for firms and funders building a book:
New MDL formation has slowed relative to the 2018–2023 wave, so the supply of fresh national litigations hasn't kept pace with the capital that wants to deploy into mass torts. That's compressed the number of torts institutional money can meaningfully scale into.
Acquisition cost has become the primary lever on IRR, more than it used to be. When a docket is mature, the difference between a well-run, vetted intake funnel and a broker reselling the same lead five times shows up directly in blended cost-per-case and in downstream attrition.
Duration risk has grown, not shrunk, even as acquisition has gotten more disciplined — bellwethers are taking longer, some defendants are litigating harder rather than settling early, and that stretches the capital's holding period independent of case quality.
Buyers have gotten more sophisticated. Funders are asking for provenance on cases — how was this claimant sourced, verified, and vetted — in a way they weren't five years ago, because the market has seen enough bad paper (duplicate leads, unverified identities, cases that don't survive record review) to know that price per case is meaningless without a quality standard behind it.
You have pointed to the rise of local single-event and niche litigation investing. What is pulling capital toward those cases and away from the large national torts, and how do the economics actually compare on volume, cycle time and predictability of outcome?
Capital is rotating toward single-event and niche litigation for a few concrete reasons:
Volume dynamics are different. A national tort's claimant pool is fixed by exposure and injury criteria and gets divided among every firm and funder in the space simultaneously. A single-event case — a mass casualty incident, an environmental release, a data breach, a building collapse — has a defined, discoverable population that isn't being fought over by the entire industry the way Roundup or talc was.
Cycle time can be meaningfully shorter. Single-event litigation often has a clearer liability picture (one incident, one set of facts, sometimes one insurance tower) rather than years of Daubert fights, science panels, and bellwether selection that stretch a pharmaceutical or device MDL. That compresses the funder's holding period.
Predictability is a trade-off, not a pure upgrade. National torts benefit from bellwether verdicts and global settlement structures that create pricing signals across thousands of cases at once — once a settlement matrix exists, valuation gets easier even if it's taken years to get there. Single-event cases don't have that luxury; each one can be closer to a one-off with its own liability and damages analysis, which raises idiosyncratic risk even as it lowers correlation risk across a portfolio. For funders, the appeal is genuinely a diversification play — smaller, faster-cycling, less-correlated bets — rather than a strictly better risk-return profile than a mature national tort.
Social media / platform-addiction litigation is the case study right now. It's not a traditional pharma or device mass tort, but it's coordinated, has thousands of potential claimants, and is drawing real funding commitments specifically because it's early — the opposite of the saturated-tort problem — while carrying its own novel-theory risk since there isn't yet a settlement matrix to underwrite against.
The honest comparison on economics: single-event and niche litigation generally win on cycle time and on diversification benefit to a portfolio; national mass torts still win on scale and on the eventual pricing clarity a mature settlement program provides. Sophisticated capital is increasingly running both books simultaneously rather than picking one lane.
Conversion rates and duration are the two variables that most often break an investor's model. What specifically does CAMG do at the intake, verification and medical-records stage to improve conversion, and what can you give investors that makes duration a more reliable input rather than a guess?
Conversion and duration break models because most of the market treats a "case" as a binary event — lead came in, contract got signed — when in reality it's a multi-stage funnel with attrition at every step, and duration is treated as a docket-wide average rather than a claimant-specific variable.
What we do to move conversion:
Identity verification at first touch. Every claimant is verified through government-issued ID and secure validation tools before records are ever requested — this front-loads disqualification of non-viable claims instead of discovering the problem after money has been spent chasing medical records.
A single, standardized intake process regardless of lead source. Whether CAMG generated the case or it came through a vetted partner, it goes through the same internal team and process. That consistency is what keeps conversion rates comparable and auditable across a large book, rather than varying wildly by which vendor sourced which batch.
Fast medical record retrieval — typically inside 48 hours when records are available — through established provider networks, so cases don't die in a queue waiting on paperwork.
Record review and validation against eligibility criteria — proof of use, injury detail, and case-relevant medical information are checked before a case is called "case-ready," not after a firm or funder has already committed capital to it.
Quality control and compliance oversight at every stage, monitored for completeness and consistency, so a funder isn't relying on our word for it — the process itself is the control.
What we give investors on duration:
CMIR, our litigation-investment reporting platform, standardizes case data across handling firms and dockets into common milestones, so a funder can see where every case in a portfolio actually sits in the litigation lifecycle — not just "filed" or "not filed," but the granular status that predicts time-to-resolution.
Smart KPIs generated from that milestone data — case valuation, funding profitability, firm-level performance — turn duration from a docket-wide guess into something benchmarked against how comparable cases and comparable handling firms have actually performed.
Firm and vendor-level drill-down. Duration isn't just a function of the tort — it's heavily a function of which firm is handling the case and how that firm litigates. Being able to segment performance by handling firm is one of the more reliable ways to convert "how long will this take" from an industry-wide guess into a firm-specific, data-backed estimate.
The throughline: conversion improves when disqualification happens early and cheaply instead of late and expensively; duration becomes a real input instead of a guess when you're tracking milestones and firm performance systematically rather than relying on docket folklore.
You have also cautioned about price versus quality. Where do you see investors and firms getting that trade-off wrong, what should a sophisticated buyer be demanding before committing capital to acquired cases, and how do you expect the case-acquisition market to shake out over the next 18 to 24 months?
Where investors and firms get the trade-off wrong: the most common mistake is anchoring on cost-per-case as if it's a standalone metric. A cheap case that fails record review, turns out to be a duplicate, or can't establish proof of use isn't cheap — it's a loss with extra steps, and it still consumed underwriting time and capital allocation. The market has plenty of buyers who compare a $2,000 case to a $4,000 case without asking what verification, record retrieval, and quality control actually happened behind each number. Price is only informative once quality is held constant, and right now it usually isn't.
What a sophisticated buyer should demand before committing capital:
Provenance, not just volume. How was each case sourced, and by whom? Was intake, verification, and record review handled by one accountable process, or resold and repackaged across multiple vendors?
Documentation, not assertions. Verified identity, retrieved and reviewed medical records, and proof-of-use documentation delivered with the case — not promised as available on request after the deal closes.
Portfolio-level reporting, not case-by-case anecdotes. Standardized milestone tracking and KPIs across the whole book, so performance can be benchmarked and duration assumptions can be tested against real data rather than the loudest success story in the room.
Transparency into the acquisition funnel itself — conversion rates, disqualification rates, and where in the process cases are dropping out — because a buyer who only sees the cases that survived has no way to judge whether the process upstream was rigorous or lucky.
How this shakes out over the next 18–24 months: expect continued consolidation around vetting and intake standards rather than around any single tort. The firms and vendors who can prove — with data, not just marketing language — that their cases convert and their duration estimates hold up will take share from brokers who are essentially reselling undifferentiated leads. I'd also expect capital to keep splitting its attention between mature national torts (where the math is well understood but the upside is compressed) and single-event/niche litigation (where the upside is better but the underwriting is harder and requires real diligence on liability, not just claimant volume). The buyers who win will be the ones treating case acquisition as a data and process discipline rather than a media-spend arms race.
